MarginsXMarginsX
Home › Markets › Health Care › TARS

Tarsus Pharmaceuticals Inc. (TARS)

TARS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$78.68
-1.99% on the day
Market cap
$3.9B
Mid cap
Revenue · 2025
$451.4M
+146.7% on 2024
Net income · 2025
-$66.4M
-14.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819790/000181979026000019/0001819790-26-000019-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTARS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2020
SEC CIK0001819790
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inDE

Financials · 2025

LineValue
Revenue$451.4M
Net income-$66.4M
Operating income-$71.0M
Net margin-14.7%
Operating margin-15.7%
Revenue growth+146.7%
Cash$183.6M
Total assets$562.2M
P/E (computed)Net income was not positive
P/S (computed)8.6×

Warning signs

Cash runway
Cash-flow positive
$136.5M cash at September 30, 2026
Share count, 1 year
+16.2%
2025-10-29 to 2026-10-29 · +48.9% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$20.0M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$136.5M cash; operating cash flow $12.5M a quarter.Report 2026-09-30
Shares outstanding49,305,552 (2026-10-29); 42,449,105 a year earlier; 33,104,612 three years earlier.Cover page 2026-10-29
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Irvine, California, United StatesPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $20.0M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$194.6M-$668.3M-$6.0M$136.5M$72.9M$682.2M10-Q 2026-11-03
Q2 2026
2026-06-30
$173.9M-$18.6M$61.2M$204.6M$72.8M$606.3M10-Q 2026-08-06
Q1 2026
2026-03-31
$162.1M-$7.0M-$24.7M$102.2M$72.6M$535.1M10-Q 2026-05-06
Q4 2025
2025-12-31
$151.7M-$8.4M$19.3M$183.6M$72.4M$451.4M10-K 2026-02-23
Q3 2025
2025-09-30
$118.7M-$12.6M$18.3M$112.7M$72.3M$366.1M10-Q 2026-11-03
Q2 2025
2025-06-30
$102.7M-$20.3M-$29.4M$96.6M$72.1M$295.5M10-Q 2026-08-06
Q1 2025
2025-03-31
$78.3M-$25.1M-$20.7M$175.8M$72.0M$233.7M10-Q 2026-05-06
Q4 2024
2024-12-31
$66.4M-$23.1M-$22.2M$94.8M$71.8M$183.0M10-K 2026-02-23

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-10-13
Latest annual report10-K2026-02-23
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 678 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+17.0%
1 month+13.4%
3 months+16.6%
Year to date-2.0%
1 year+10.7%
From 52-week high-11.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
CRSPCRISPR Therapeutics AG Common Shares$40.37-4.43%$3.9B
RLAYRelay Therapeutics Inc.$17.27-4.53%$3.8B
IOVAIovance Biotherapeutics Inc.$7.55-2.71%$3.5B
ADPTAdaptive Biotechnologies Corporation$27.87-4.03%$4.5B
ADMAADMA Biologics Inc$13.47-1.54%$3.0B
VCELVericel Corporation$57.48+0.91%$2.9B
DNLIDenali Therapeutics Inc.$18.08-3.52%$2.9B
SRRKScholar Rock Holding Corporation$44.54+3.09%$5.4B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier